Private Label Cosmetic Actives — The Concept-to-Lot Workflow for Indie Brands
Private label, white label, OEM, ODM, contract manufacturing — different terms for partly-overlapping workflows that get a finished product to a brand without the brand running its own manufacturing. What each model actually means, the realistic timeline for each, and where peptide actives fit in the decision tree.
Published May 25, 2026 · 7 min read · By Pepoderma Regulatory Team
An indie brand launching a cosmetic product without in-house manufacturing capability has several routes to a finished product. The terminology — private label, white label, OEM, ODM, contract manufacturing — is used loosely in the industry and often interchangeably, but the underlying models are distinct in cost, timeline, brand differentiation, and IP ownership. This Note maps the models, the realistic timelines, and the implications for incorporating peptide actives into a brand's first product line.
The four models, with operational distinctions
Private label (also "white label") — the manufacturer has already developed a finished product. The brand selects from the manufacturer's catalog of pre-formulated products, customizes the packaging and label, and the manufacturer fills and ships under the brand's name. The formula is the manufacturer's; the brand owns the packaging design, label content, and marketing.
OEM (Original Equipment Manufacturer) — the brand provides the formula specifications (sometimes a full formulation, sometimes a target performance brief) and the manufacturer produces to those specifications. The formula may be co-developed or supplied complete; the manufacturer's contribution is the production capability. The brand typically owns the formula.
ODM (Original Design Manufacturer) — the manufacturer develops a custom formula for the brand based on the brand's brief, then produces it. The manufacturer's R&D team is involved in the formulation work. IP arrangements vary — some ODM deals give the brand exclusive use of the formula; others retain manufacturer ownership with non-exclusive licensing to the brand.
Contract manufacturing (CMO) — the brand has its own formula, holds the IP, and contracts production capacity from the manufacturer. This is the model most typical of established brands with internal R&D; the manufacturer is a service provider rather than a partner.
In practice, the lines blur. Many "private label" deals include light customization of an existing base. Many "OEM" deals have the manufacturer doing more development work than the term implies. Brands need to be precise about what they're getting at the contract stage.
Realistic timelines
The timeline for going from brand concept to product on shelves varies by model:
| Model | Typical timeline | What drives it |
|---|---|---|
| Private/white label (no formula change) | 4-12 weeks | Packaging customization + label artwork + production scheduling + first-lot stability bridging |
| Private label with light customization (fragrance / color / claim) | 8-16 weeks | Adds reformulation cycle + accelerated stability on the customized variant |
| OEM (existing formula adapted) | 8-16 weeks | Specification clarification + raw material sourcing + first-batch production |
| ODM (custom formula) | 6-12 months | R&D cycle (3-6 months) + stability testing (3 months minimum for accelerated; longer for real-time) + regulatory documentation + first commercial batch |
| Contract manufacturing (brand owns formula) | 4-12 weeks | Manufacturing capacity scheduling + raw material procurement + production |
The fastest path is private label with no formula change; the slowest is ODM. Custom formulation with stability and regulatory work is rarely under 6 months from brief to first lot.
The single biggest schedule risk is brand-side decision-making speed. Manufacturers can hold to their stated timeline if the brand makes packaging, label, and approval decisions on schedule. Late changes (new colorway, revised front-of-pack copy, fragrance preference shift) commonly add weeks per change.
Where peptide actives fit in the decision tree
For a brand wanting a peptide active in its first product:
If the peptide is well-established (GHK-Cu, Argireline, Matrixyl, palmitoyl tripeptides): - Private label is feasible — many manufacturers stock pre-formulated bases with these actives - The brand chooses concentration tier (e.g. 0.05%, 0.1%, 0.5% GHK-Cu), packaging, and label - Fastest to market; lowest brand differentiation since competitors can buy the same base
If the peptide is a specific named complex or supplier-exclusive blend: - OEM or ODM — the brand specifies the active, the manufacturer formulates around it - Allows brand differentiation through the active choice - 12-16 weeks for OEM, 6+ months for ODM
If the peptide is novel (custom-synthesized or proprietary combination): - ODM with the manufacturer's R&D team - 6-12 months timeline - Allows the strongest brand differentiation but with the highest schedule and cost commitment
The cost dimension
Capital required for a first product launch varies dramatically by model:
- Private label, single SKU, no customization: typically $3,000-$15,000 for first lot, depending on lot size (often 500-2,000 units MOQ); per-unit cost includes manufacturer margin
- Private label with customization: $5,000-$30,000 for first lot
- OEM: $10,000-$80,000 for first lot, including specification work and stability testing
- ODM: $50,000-$300,000+ for product development, stability testing, regulatory work, and first commercial lot
- Contract manufacturing with brand-owned formula: depends on the existing formula's stage of readiness; can be similar to OEM if formula is production-ready, similar to ODM if formula needs production-scaling work
These are rough indicative ranges; specific quotes vary widely by manufacturer, geography, formula complexity, and packaging.
What Pepoderma provides for private-label / OEM / ODM workflows
Pepoderma supplies the cosmetic-grade peptide actives. The brand's relationship is typically with a contract manufacturer (separate company) for the finished product; Pepoderma's role is as the upstream active supplier.
For brands using a contract manufacturer: - Direct supply to the manufacturer — Pepoderma ships actives directly to the manufacturer with the brand's PO, with COAs going to both parties - Specification support during the OEM/ODM formulation phase — our regulatory and formulation team works with the brand's chemist (or the manufacturer's R&D) on active concentration, carrier compatibility, and stability projections - Sample lots for stability bridging — small-volume samples at the same release quality as commercial lots, so the manufacturer can run early stability and prototype work - Trace-and-track documentation — full chain of custody from Pepoderma synthesis through manufacturer to the brand's finished product
For brands wanting an integrated private-label-like experience including the active: - We maintain a list of vetted contract manufacturers experienced with Pepoderma's actives in standard cosmetic formulations - Referral to the right manufacturer cuts the "manufacturer search" stage from 4-8 weeks to 1-2 weeks for brands without existing manufacturing relationships
The common failure mode to avoid
The most expensive mistake indie brands make: committing to a manufacturer based on lowest first-lot cost without verifying the manufacturer's quality systems and the active-supply chain. A low first-lot cost often hides: - Substituted actives (the COA shows the labeled INCI but the actual material may be a lower-grade equivalent) - Inadequate stability testing - Compliance gaps on the manufacturer's GMP certification
The vetting work — visit (or video-tour) the manufacturer, request COAs for the actual lot of your active that they're using, confirm the GMP certification, ask for stability data on the proposed formulation — is the safeguard. Costs a few extra weeks; saves substantial post-launch enforcement and quality risk.